Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1012

Enrollment

INDUSTRY

Sponsor class

Conditions

Hormone-Sensitive Prostate Cancer

Interventions

DRUG: Capivasertib
OTHER: Placebo
DRUG: Abiraterone Acetate

Sponsor

AstraZeneca